Quick Facts

• Therapeutic Domain: Respiratory conditions
• Key Uses: Managing symptoms of asthma and Chronic Obstructive Pulmonary Disease (COPD)
• Relief Provided: Helps alleviate wheezing, shortness of breath, and chest tightness associated with airflow obstruction.

---

What Theophylline Treats: Main Uses and Benefits

Theophylline is a medication utilized in the management of certain respiratory conditions that involve a narrowing of the airways. Its primary use is as an agent in the treatment of chronic asthma and Chronic Obstructive Pulmonary Disease (COPD), which includes chronic bronchitis and emphysema.

The medication is administered to help support breathing by addressing the symptoms associated with these conditions. It contributes to symptom relief, such as reducing the occurrence of wheezing, shortness of breath, and chest tightness that results from airway obstruction. For patients with persistent breathing difficulties, Theophylline is often considered a supplemental therapy when control is not achieved with standard inhaled treatments.

It is important to understand that this drug is intended to assist in controlling chronic symptoms but does not provide immediate relief for sudden, acute breathing distress. The therapeutic role of Theophylline is well-established in addressing reversible airflow obstruction.

Therapy with this medication may also be indicated to manage breathing irregularities in premature infants, an associated, distinct application for the drug.

Regulatory References

1. NIH StatPearls clinical overview

The eligibility profile for Theophylline is defined by a primary absolute prohibition and several severe conditional restrictions based on physiological clearance capacity and co-morbidity risk.

The medicine is absolutely contraindicated for patients with a known hypersensitivity or allergy to theophylline or any other xanthine derivative. Use may also be prohibited for patients with certain cardiac conditions, such as coronary artery disease.

Eligibility is highly restricted for populations whose physiological status significantly impairs drug clearance, increasing the risk of toxicity. This includes individuals with severe hepatic impairment (e.g., cirrhosis), severe systemic infection (sepsis), and congestive heart failure. Older adults (over 60 years) are subject to restrictions due to predictably decreased drug clearance.

Use is conditional for patients with certain pre-existing conditions that may be exacerbated, such as active peptic ulcer disease, existing seizure disorders, and cardiac arrhythmias. For age-specific rules, the medicine is generally approved for adults and children over one year of age, but use in infants younger than one year is typically not recommended. During pregnancy (Category C) and lactation, eligibility is conditional, permitted only when the labeled maternal benefit justifies the potential risks.

Interactions with Other Medicines and Products

Theophylline is extensively metabolized by the cytochrome P450 enzyme system, primarily CYP1A2, making its plasma concentrations susceptible to change when co-administered with other medicines that affect this system. Due to Theophylline's narrow therapeutic window, any significant concentration change necessitates close monitoring and dose adjustment.

Documented Pharmacokinetic Interactions

Interaction Type	Examples of Interacting Medicines or Products	Interaction Mechanism & Resulting Constraint
Increased Theophylline Levels (Toxicity Risk)	Cimetidine, Macrolides (e.g., Erythromycin), Quinolones, Zileuton	Inhibition of hepatic metabolism (CYP1A2), significantly reducing Theophylline clearance. Requires dose reduction and close monitoring.
Decreased Theophylline Levels (Efficacy Loss)	Barbiturates (e.g., Phenobarbital), Phenytoin, Carbamazepine, St. John's Wort	Induction of hepatic metabolism, accelerating Theophylline clearance. Requires dose increase and close monitoring.

Documented Pharmacodynamic and Other Interactions

Concomitant use of Theophylline with other xanthine-containing preparations (including caffeine and similar substances) must be avoided due to the increased risk of additive adverse effects. Theophylline may reduce the therapeutic effect of Lithium carbonate and Adenosine. Additionally, beta-blockers may decrease Theophylline elimination, while Theophylline may decrease the action of beta-blockers. High dietary intake of caffeine-containing beverages and chocolate should be limited, as this may also increase the risk of adverse reactions and interfere with drug testing. Smoking accelerates Theophylline metabolism, necessitating higher doses in patients who smoke.

Cellular Mechanism: Inhibition of Phosphodiesterase

The primary mechanism of Теофиллин involves the non-selective inhibition of Phosphodiesterase (PDE) enzymes, particularly PDE3 and PDE4, within the bronchial smooth muscle. This competitive action prevents the hydrolysis of cyclic adenosine monophosphate (cAMP). The resulting elevation in the intracellular concentration of cAMP initiates a downstream cascade that decreases free intracellular calcium ions ( Ca^2+). This mechanism directly causes the relaxation of the bronchial smooth muscle tissue.

Immunomodulation: Gene Regulation and Receptor Blockade

Theophylline exerts a second crucial mechanism through the modulation of inflammatory processes, independent of its PDE-inhibitory action. It functions as a non-selective antagonist of Adenosine Receptors and enhances the activity of Histone Deacetylase 2 (HDAC2). The HDAC2 activation suppresses the expression of pro-inflammatory genes, while Adenosine receptor blockade prevents signals that promote constriction. This combined action results in the physiological reduction of airway hyperresponsiveness.

How to Use Theophylline — General Administration Principles

The use of Theophylline is structured by a highly individualized approach that relies on careful dose adjustment, rather than fixed schedules. The main routes of administration are oral for long-term maintenance therapy and intravenous (IV) infusion for use in controlled hospital settings, such as during initial stabilization.

---

Dosing and Frequency Patterns

The most important administration principle is Therapeutic Drug Monitoring (TDM). All maintenance dosing is guided by measured serum concentrations to ensure levels remain within the therapeutic range (typically 10 - 15 mcg/mL in adults).

Feature	Administration Principle
Dosing Schedule	Initial dosing starts low and must be gradually increased (titrated) over intervals of no less than 3 days until steady blood concentrations are achieved.
Frequency	Immediate-release forms are administered in divided doses (e.g., every 6 to 8 hours). Sustained-release forms are typically administered once or twice daily to provide a prolonged effect.
Specific Conditions	Doses for the IV route are calculated based on ideal body weight, not actual body weight.

---

Administration Requirements and Adjustments

For proper administration, sustained-release tablets or capsules must be swallowed whole and must not be crushed or chewed, as this compromises the controlled-release mechanism. Consistent administration with respect to meals (always with food or always without) is advised for consistent absorption.

Specific dosage modifications are required for certain populations. Older adults and individuals with hepatic impairment require a lower initial starting dose and reduced maintenance doses due to decreased drug clearance, which is a mandatory consideration in the administration protocol. If a dose is missed, the standard procedure is to skip it and take the next dose at the usual time.

Research Evidence / Overview of Studies

Phase III Clinical Trials

Research was primarily conducted through randomized, placebo-controlled, double-blind Phase III clinical trials involving participants diagnosed with the target condition. These studies form the primary body of evidence regarding the investigational drug.

• Core Findings Evaluated: Research focused on the drug's activity in a specific inflammatory pathway. Researchers in initial studies examined its effect on daily function and the frequency of flare-ups, compared to placebo. Research explored whether the drug was associated with a reduction in symptoms for participants in trials lasting 12 weeks. Outcomes were typically measured using validated, patient-reported severity scales.

• Inflammation and Biomarkers: Investigators also evaluated the drug's effect on circulating inflammatory biomarkers. A key finding indicated investigators' interest in the drug's potential role in influencing inflammation pathways. Differences in biomarker levels between the active treatment group and the placebo group were analyzed.

• Extended Observation Data: Following the 12-week trials, data was collected from a subset of participants in subsequent extension research. This research evaluated observed changes and their persistence over an extended period. Findings suggested that a proportion of participants maintained initial observed changes in symptom scores.

Secondary Research and Combination Approaches

• Comparison to Other Treatments: A separate Phase III study explored whether a combination therapy showed different outcomes when compared to monotherapy with the standard-of-care drug. This research focused on the primary endpoints of daily function and symptom severity. Some studies explored the effects of using the drug in conjunction with other non-pharmacologic interventions, such as physical therapy.

• Specific Patient Populations: Research focused on people with mild-to-moderate forms of the condition. Separate, smaller exploratory studies were conducted to gather preliminary data on people with severe or refractory forms. Further investigation is needed to determine whether findings in the mild-to-moderate population would be consistent in the severe population.

• Molecular and Tissue Studies: Preclinical and translational research investigated the drug's influence at the cellular level. Other studies suggest investigators explored its role in tissue damage observed in the condition, often using in vitro models. These studies provided information on the drug's biological activity.

Key Studies & References Long-term Efficacy and Safety of Low-Dose Theophylline in Mild-to-Moderate Chronic Obstructive Pulmonary Disease

Common questions about Теофиллин (FAQ)

Q: What conditions is Theophylline used to treat?

Official regulatory documents indicate that Theophylline is used to prevent and treat symptoms associated with certain lung diseases. This includes managing conditions such as asthma, chronic bronchitis, and emphysema (which are types of COPD). It may also be used in controlled settings to treat specific breathing issues in premature infants.

Q: What is the difference between immediate-release and sustained-release Theophylline?

The difference relates to the schedule of administration. Immediate-release forms must be taken in divided doses throughout the day to maintain consistent levels. In contrast, sustained-release forms are designed to release the medicine gradually, allowing for a less frequent dosing schedule, typically only once or twice daily.

Q: Why can't I crush or chew sustained-release Theophylline tablets?

Regulatory sources strictly advise against crushing or chewing sustained-release tablets; they must be swallowed whole to maintain their controlled-release function. Crushing or chewing them is understood to compromise the mechanism, which can lead to a rapid release of the medication. This rapid release, sometimes called dose-dumping, significantly increases the risk of adverse reactions and toxicity.

Q: What should the Theophylline serum concentration be?

Therapeutic drug monitoring is used to ensure the amount of medicine in the blood remains within a safe and effective range. The established therapeutic concentration range that prescribers generally aim for in adults is between 10 and 15 micrograms per milliliter (mcg/mL). Concentrations above 20 mcg/mL are associated with a much higher risk of serious toxicity.

Q: What are the early signs of Theophylline toxicity?

Official safety guidelines state that early signs of the drug accumulating to toxic levels can include symptoms such as persistent nausea or vomiting, a severe headache, increased restlessness, trouble sleeping (insomnia), or a rapid heart rate. Official safety guidelines recommend seeking immediate medical attention if these symptoms are noted, as they can be warning signs of serious toxicity.

Q: Can I drink coffee or other caffeine products while taking this medication?

Theophylline and caffeine are chemically related, and consuming high amounts of caffeine-containing products may increase the likelihood of side effects. This includes beverages like coffee, tea, and cola, as well as chocolate. Official product information notes that limiting high dietary intake of caffeine is necessary, as combining it with the medicine may increase the risk of side effects such as tremors, rapid heart rate, and trouble sleeping.

Q: How does Theophylline interact with smoking?

According to regulatory information, smoking tobacco or marijuana causes the body to break down and eliminate Theophylline much faster than usual. This means that people who smoke may require a higher dose of the medication to achieve a therapeutic level. Changes in smoking habits (starting or stopping) are expected to require a dose adjustment, and official information emphasizes the need to inform the prescriber of any changes.

Storage and Disposal of Theophylline

To maintain product stability, Theophylline must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be kept in its original container, tightly closed, and protected from excess heat and moisture; storage in a bathroom is prohibited. Oral solutions may require protection from light.

All forms of Theophylline must be stored out of the sight and reach of children in a secure, up-and-away location. The container should have a child-resistant closure.

Disposal of unused or expired product should follow official procedures, preferably by using a community drug take-back program. If this is not an option, follow the FDA's guidance for household disposal, mixing the drug with an undesirable substance and placing it in a sealed bag; the product must not be flushed down the toilet or released into wastewater.